As I've said here many times, this is the way Andexanet becomes a commercial success. The various institutions that publish formulary and treatment guidance documents are lining up nicely listing A as the preferred treatment for reversal, some like the Anticoagulation Forum, even recommending off label use.
If all that was available were the trial data and FDA documents, there is wiggle room for hospitals to make the argument that the data are equivocal and the cost is not justified, but when the various expert guidance forums all line up with a "preferred" treatment option, it becomes problematic. You do not want to be perceived as not offering the best available care options and liability becomes a consideration.